Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Rory M.C. Abrams; Brian D. Kim; Desiree M. Markantone; Kaitlin Reilly; Alberto E. Paniz-Mondolfi; Melissa R. Gitman; S. Yoon Choo; Winona Tse; Jessica Robinson-Papp

doi:10.1007/s13365-020-00884-7

Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Rory M.C. Abrams
, Brian D. Kim
, Desiree M. Markantone
, Kaitlin Reilly
, Alberto E. Paniz-Mondolfi
, Melissa R. Gitman
, S. Yoon Choo
, Winona Tse
, Jessica Robinson-Papp

School of Medicine

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

Original language	English
Pages (from-to)	797-799
Number of pages	3
Journal	Journal of NeuroVirology
Volume	26
Issue number	5
DOIs	https://doi.org/10.1007/s13365-020-00884-7
State	Published - 1 Oct 2020

Keywords

Coronavirus-19
Guillain-Barré syndrome
Neuromuscular disorders
Polyneuropathy
SARS-CoV-2

Access to Document

10.1007/s13365-020-00884-7

Cite this

@article{678ec8fc5ab84200b4ec66f632572998,

title = "Severe rapidly progressive Guillain-Barr{\'e} syndrome in the setting of acute COVID-19 disease",

abstract = "There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barr{\'e} syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.",

keywords = "Coronavirus-19, Guillain-Barr{\'e} syndrome, Neuromuscular disorders, Polyneuropathy, SARS-CoV-2",

author = "Abrams, \{Rory M.C.\} and Kim, \{Brian D.\} and Markantone, \{Desiree M.\} and Kaitlin Reilly and Paniz-Mondolfi, \{Alberto E.\} and Gitman, \{Melissa R.\} and Choo, \{S. Yoon\} and Winona Tse and Jessica Robinson-Papp",

note = "Publisher Copyright: {\textcopyright} 2020, Journal of NeuroVirology, Inc.",

year = "2020",

month = oct,

day = "1",

doi = "10.1007/s13365-020-00884-7",

language = "English",

volume = "26",

pages = "797--799",

journal = "Journal of NeuroVirology",

issn = "1355-0284",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

AU - Abrams, Rory M.C.

AU - Kim, Brian D.

AU - Markantone, Desiree M.

AU - Reilly, Kaitlin

AU - Paniz-Mondolfi, Alberto E.

AU - Gitman, Melissa R.

AU - Choo, S. Yoon

AU - Tse, Winona

AU - Robinson-Papp, Jessica

PY - 2020/10/1

Y1 - 2020/10/1

N2 - There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

AB - There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

KW - Coronavirus-19

KW - Guillain-Barré syndrome

KW - Neuromuscular disorders

KW - Polyneuropathy

KW - SARS-CoV-2

UR - https://www.scopus.com/pages/publications/85088568918

U2 - 10.1007/s13365-020-00884-7

DO - 10.1007/s13365-020-00884-7

M3 - Article

C2 - 32720233

AN - SCOPUS:85088568918

SN - 1355-0284

VL - 26

SP - 797

EP - 799

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

IS - 5

ER -

Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this